Menu Close

29 Speakers From The Pharmaceutical Industry, Patient Advocacy Groups & Patients Themselves In 1 Day!

Next-Level Strategies To Embed Patients At The Heart Of Organisational Decision Making & Build Empowering Relationships With Advocacy Groups For Long-Term, Value-Adding Patient Centricity, Engagement & Partnerships
Develop Long-Term Relationships With Patients & Advocates Through Patient-Centric Strategies Which Inform All Aspects Of The Pharma Lifecycle ✓ Embed
Patient Voice & Increase Early Patient Involvement & Co-Creation To Boost Patient Experiences, Journeys & Digital & Virtual Engagement ✓ Engage Internal &
External Stakeholders To Overcome Barriers To Patient Centricity. A One-Day, Practitioner-Led Conference & Networking Event, 24th May 2022, Central London

08.30 Registration, Informal Networking & GIC Opening Remarks

09.00 Morning Chair’s Opening Remarks

Paul Edwards, Director of Clinical Services, Dementia UK

PATIENTS AT THE HEART OF DECISION MAKING - Double Perspective

09.10 Walk The Walk Of Patient Centricity With Practical Steps To Place The Patient At The Centre Of All Business Decisions

  • How can pharma companies move past talking about patient centricity, and take direct action to involve patients in every part of the journey and truly
    centre around the patient?
  • But I’m not customer facing! Contextualise patient needs throughout the organisation to ensure all decision making and design has the patient at its heart
  • Collaboration is key to patient engagement, so how can pharma work more strategically with patient organisations and develop relationships that boost engagement and outcomes?

09.10 Jost Leemhuis, Head of Safety Science, Roche

09.30 Arnaud Muller, Digital Portfolio Director, Specialty Medicines, Daiichi Sankyo

LONG-TERM PATIENT ENGAGEMENT - PANEL DISCUSSION & Q&A

09.50 Move Beyond Ad-Hoc Engagement To Develop Long-Lasting Relationships That Strengthen Patient Involvement & Embeds Them Into Business Decision Making

  • Patient panels? Podcasts? What innovative methods can be used to engage patients long-term throughout the patient and pharma lifecycle?
  • Improve listening and action feedback to enhance the patient experience
  • What support do patients and advocacy groups need to be able to consistently engage with pharma companies, and what role do pharma brands have in facilitating this?
  • Phase four isn’t the end! Keep engagement strong post phase four to ensure the patients voice is heard continuously beyond the development process

Gunnar Schroefel, Global Director Patient Advocacy, Oncology, Daiichi Sankyo

Lucie Williams, Global Head of Patient Centricity & Medical Excellence

John Ioannou, Head of Global Medical Affairs, Rheumatology, UCB

Stephen Head, Senior Director, Patient Partnerships, Astellas Pharma Europe Ltd

Geoff Rollason, Patient Experience & Service Director, Pfizer UK

Paul Robinson, European Lead, Patient Innovation, MSD

Matthew Hunt, Managing Director, 11 London

LEVELLED-UP ADVOCACY COLLABORATION

10.20 Strengthen Relationships With Patient Advocacy Groups To Solidify Patient Engagement For The Future

  • How can we best identify the needs of advocacy groups, so that partnership and collaboration can demonstrably improves patient experiences?
  • What do advocacy and patient groups need and expect from the pharmaceutical industry in order to effectively advocate for patients?
  • Adapt your engagement strategies for both large and small advocacy groups and meet their differing needs to ensure deep-rooted collaboration

Henry Featherstone, Global Public Affairs, General Medicines, Sanofi

10.40 Morning Refreshment Break With Informal Networking

DIGITAL PATIENT ENGAGEMENT

11.10 Develop Seamless Online Experiences For Patients & Support Them Through Virtual Engagement Programmes To Reach Your Audience Effectively

  • 2021 was the year of the app, but how can we build upon these and confidently engage all patients through digital and virtual channels?
  • How can pharma companies take a systematic approach to engaging with patients digitally and truly embed this as a strong engagement channel?
  • Remove barriers and support patients through digital engagement to enhance your reach without engagement levels dropping off

BONUS SESSION

11.30 Bonus Session; Reserved For Exclusive Conference Partner

PATIENT PERSPECTIVES - PANEL DISCUSSION & Q&A

12.00 Patients’ Honest Perspectives On Their Relationship & Experiences With Pharma & How Their Voice Can Boost Patient & Business Outcomes

  • What do patients expect and need from the pharmaceutical industry and how can pharma focus on the issues that truly matter to patients?
  • How can pharma help patients feel more comfortable to become advocates and evidence their voices are being heard and their efforts are valued?
  • What areas of the pharma process do you feel your voice is missing and how can pharma adapt to include patient insights more successfully in these areas?

Rebecca Langley, Patient Advocate

Olive Fulton, Patient Advocate

Dany Bell, Strategic Advisor Treatment, Medicines & Genomics, Macmillan Cancer Support

Mary Lynne van Poelgeest-Pomfret, President, WFIPP

PATIENT-CENTRIC CLINICAL TRIAL DESIGN

12.30 Listen To & Action The Patient Voice Throughout Clinical Trials & Design Trials That Authentically & Meaningfully Engage Patients & Produce Win-Win Results

  • How can we really understand patients’ needs and voices early in the clinical trial process, and harness their insights to improve patient experiences and reduce drop-off rates?
  • Engage across national boundaries with differing regulations to drive patient recruitment and trial success
  • Successfully co-create clinical trial design with patients and harness early patient involvement secure stronger patient outcomes and improve speed-to-market

Kimberley Kallsen, Head of Patient & Site Journey, Global, Clinical Development & Operations, Boehringer Ingelheim

12.50 Morning Chair’s Closing Remarks

Paul Edwards, Director of Clinical Services, Dementia UK

13.00 Lunch For Delegates, Speakers & Partners

PEER-TO-PEER DISCUSSIONS

13.30 Informal Peer-To-Peer Discussions

A) Patient Recruitment In Clinical Trials

Eliana Triggiani, Global Patient Solutions Associate, Director R&D, AstraZeneca

B) Medical Devices, Apps & Digital Health

Tracey Robertson, Patient & Site Engagement Process Lead - Global Clinical Development & Operations, Boehringer Ingelheim

C) Pharma Reputation

D) Reimbursement

14.00 Afternoon Chair’s Opening Remarks

Dr Helen Bulbeck, Director of Policy & Services, brainstrust - the brain cancer people

OVERCOMING BARRIERS TO PATIENT CENTRICITY - PANEL DISCUSSION & Q&A

14.10 Effective Tactics To Overcome Both Internal & External Obstacles & Ensure Organisations Authentically Embrace Patient Centricity & Commit To Action

  • The message of patient centricity is getting through, but how can we inspire action internally to truly develop processes and organisations that place the patient at the centre?
  • With smaller networks of patients and advocacy groups for rare diseases, what steps can be taken to strengthen these groups and support them as valued collaborators which keep pace with other more developed therapy areas?
  • How can internal silos be broken through to ensure patient centricity is a key focus company-wide?
  • With ROI on patient centricity projects difficult to measure, how can the benefits be communicated clearly to ensure everyone is on the same page?

Marco Koch, Director Early Patient Voice Lead, UCB

James Fitzpatrick, Senior Director & Head of Public, Affairs UK & Ireland, Sanofi

Helen Stoop, Head of Patient Advocacy, Europe & Canada, Takeda

Garry Brough, Lead for Peer Learning, Partnerships & Policy, Positively UK

BONUS SESSION

14.40 Bonus Session; Reserved For Exclusive Conference Partner

PATIENT JOURNEYS

15.10 Collaborate Effectively & Engage Patients Throughout Their Journey To Demonstrably Improve Experiences & Outcomes

  • In which areas of patient journeys can pharma generate the deepest impact and bring tangible benefits to the patient experience?
  • How can patients and advocates guide pharma on weaker aspects of the patient journey where they aren’t being heard, and bring their insights into these spaces?
  • Harness key digital tools to remove pain points from patient journeys and create seamless experiences

Geoff Rollason, Patient Experience & Service Director, Pfizer UK

PATIENT CENTRICITY & DEVELOPING COUNTRIES: CHALLENGES & CHANCES - CASE STUDY

15.30 Navigate The Pitfalls & Create Opportunities To Engage Patients In Developing Countries With Adaptable & Flexible Patient Engagement & Centricity Strategies

Gunnar Philipp, Senior Director Medical Affairs, Intercontinental, CSL Behring AG

15.50 Afternoon Refreshment Break With Informal Networking

STAKEHOLDER COLLABORATION - PANEL DISCUSSION & Q&A

16.20 Develop Meaningful Collaboration Across Healthcare Stakeholders To Focus Values & Actions On Patient Centricity & Outcomes

  • Align values across multiple stakeholders to ensure all parties are moving in the direction that truly matters to patients
  • What are best practice examples of partnering and co-creation between patient advocacy groups and pharma?
  • How can we work together to build capacity in advocacy and elevate the patient voice in healthcare and broader society?
  • With the variety of different maturities and resources spread across patient groups, how can we collaborate with equal effectiveness across differing groups, ensuring all patients are represented?

Arup Pramanik, Head of Global Market Access TA, Inflammation, Boehringer Ingelheim

Suzanne Bruins, Associate Director Public Affairs & Patient Advocacy, Gilead Sciences

Aysegül Dalbeler, Head of Medical & Scientific Affairs, Novo Nordisk

Catherine Wood, Head of Patient Experience, Breast Cancer Now

Alison Dunlop, Senior Director, Patient Advocacy, MHP Health

EDUCATION, CO-CREATION, COLLABORATION

16.50 Collaborate With Patients & Advocates To Co-Create Materials That Reach, Engage & Educate Different Patient Groups

  • What steps can be taken to combat misinformation online and ensure accurate, trustworthy information rises to the top to keep patients informed and prevent alarm or distrust?
  • Advanced therapeutics bring new challenges in patient education, how can we ensure patients have the right information to make an informed choice when advanced therapeutics are on the table?
  • Amplify your message and positively engage with different communities and patient cohorts through co creation of educational materials

Dr Lesley Booth MBE, Director of Research & PPIE, Bowel Research UK

17.10 Afternoon Chair’s Closing Remarks & Official Close Of Conference

Dr Helen Bulbeck, Director of Policy & Services, brainstrust - the brain cancer people

4 pics across